Immune and Inflammatory Indices in Peripheral Blood Predict Prognosis of Glioma and Correlate With Grades and Subtypes

NCT05635435 | Unknown

• 1 other identifier: ShengZhong
• Study Type: observational
• Target: 1,282
• Locations: 1 country
• Sites: 3

Brief Summary

Our study considered the relevant immune and inflammatory indices, such as immunoglobulin kappa light chain, TNF, and CD4+ Helper T lymphocyte% in a multi-institutional study with a large patient cohort (n=1282) from the east, northeast, and southeast of China. Our study shed light on the association of peripheral immune system status with prognosis, tumor grade, and subtype of glioma, which can potentially benefit future diagnostic and prognostic processes of glioma given its noninvasive nature. Moreover, the preoperative inflammatory status can be leveraged for timely interventions to reverse the immunosuppressive status of cancer patients and enhance anti-tumour immunity of glioma.

Conditions

Glioma; Immune Suppression

Outcome Measures

Primary Outcomes (1)

• all-cause mortality

  For this study, the endpoint was all-cause mortality. Time zero was set at the time of resection of the primary tumor.

  16 years

Study Arms (1)

primary glioma patients

We collected the information of clinical characteristics, inflammatory factors and immune factors of patients with primary glioma.

Other: Detection of Immune and Inflammatory Indices in Peripheral Blood

Interventions

Detection of Immune and Inflammatory Indices in Peripheral Blood OTHER

We detected immune and inflammatory indices in peripheral blood at each patient's at first hospitalizatin from October 13th, 2006, to April 6th, 2022.

primary glioma patients

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

In our cohort, there were more males (count, 761, percentage, 59.39%) than females. In addition, 762 patients (percentage, 59.4%) were diagnosed as grade IV glioma according to 2021 WHO criteria, which was far more than the other grades in our study. Similar characteristics were observed in the glioma subtype. IDH1 mutation status, 1p/19q codeletion status and MGMT promoter methylation status were known in 924, 771, and 855 patients, respectively. Among them, 630 of 924 patients were IDH1 mutant type, 124 of 771 patients had 1p/19q codeletion, and 369 of 855 patients were MGMT methylated. In addition, 916 patients received chemotherapy within one month after the resection of primary glioma, while 940 patients received radiotherapy postoperatively.

You may qualify if:

• glioma grading and classification histologically verified in a resection or biopsy specimen according to 2016 WHO criteria;
• age \> 18 years;
• primary malignant glioma;
• the duration of follow-up \> 3 months;
• available data of lymphocyte subsets, cytokines, immune proteins and immune complements measured at the patient's first hospitalization.
• Exculsion Criteria:
• current infectious disease, hyperpyrexia, hematological disease, diabetes mellitus, serious heart disease, hypertension, metabolic syndrome, severe renal or hepatic dysfunction, other cancer, autoimmune disease, inflammatory disease, or medication usage related to an inflammatory condition;
• prior cancer-specific pretreatment, such as chemotherapy or radiotherapy;

Sponsors & Collaborators

• Sun Yat-sen University: lead

Study Sites (3)

Xuanwu Hospital, Capital Medical University

Beijing, Beijing Municipality, 10000, China

RECRUITING

Sun Yat-sen University Cancer Center

Guanzhou, Guangdong, 510000, China

COMPLETED

The First Bethune Hospital of Jilin University

Changchun, Jilin, 130000, China

RECRUITING

MeSH Terms

Conditions

Glioma

Condition Hierarchy (Ancestors)

Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue

Central Study Contacts

Sheng Zhong, M.D.

CONTACT

18743037749; zhongsheng@sysucc.org.cn

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinical Professor

Study Record Dates

• First Submitted: November 21, 2022
• First Posted: December 2, 2022
• Study Start: October 13, 2006
• Primary Completion: April 6, 2022
• Study Completion: December 20, 2023
• Last Updated: July 12, 2023

Record last verified: 2023-07

Locations

CN (3)